Evolving treatment strategies in CML - moving from early and deep molecular responses to TKI discontinuation and treatment-free remission: is there a need for longer-term trial outcomes?

Creative Commons License

Eskazan A. E.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, cilt.84, sa.8, ss.1635-1638, 2018 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Editöre Mektup
  • Cilt numarası: 84 Sayı: 8
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1111/bcp.13637
  • Dergi Adı: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1635-1638
  • Anahtar Kelimeler: chronic myeloid leukaemia, deep molecular response, discontinuation, early molecular response, treatment-free remission, tyrosine kinase inhibitor, CHRONIC MYELOID-LEUKEMIA, TYROSINE KINASE INHIBITORS, CHRONIC-PHASE, ADVERSE EVENTS, IMATINIB, NILOTINIB, DASATINIB, BOSUTINIB, THERAPY, DISEASE
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet